Omalizumab en dermatología

  • Victoria Lucía Dávila
  • Margarita María Velásquez
Palabras clave: omalizumab, urticaria crónica, Dermatitis atopica, penfigoide ampolloso, mastocitosis cutánea.

Resumen

El omalizumab es un anticuerpo monoclonal ‘humanizado’ que se une selectivamente a IgE libre, inhibiendo su unión a los receptores, tanto el de alta afinidad (FceRI) en la superficie de mastocitos y basófilos, como el de baja afinidad (FceRII). Actualmente, se encuentra aprobado por la Food and Drug Administration (FDA) para el tratamiento del asma grave no controlada; sin embargo, existen otras enfermedades en las cuales se ha demostrado su efectividad. Condiciones dermatológicas como la urticaria crónica, la dermatitis atópica, la mastocitosis cutánea y el penfigoide ampolloso, son algunas de ellas. Esta revisión se enfoca en documentar los hallazgos sobre el uso del omalizumab en el tratamiento y control de enfermedades cutáneas.

Biografía del autor/a

Victoria Lucía Dávila

Médica, Universidad Pontificia Bolivariana, Clínica Cardiovid, Medellín, Colombia

Margarita María Velásquez

Dermatóloga y doctora en Ciencias Básicas Biomédicas, énfasis en Inmunología; profesora, Sección de Dermatología, Centro de
Investigaciones Dermatológicas CIDERM, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

Referencias bibliográficas

1. ncorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E. Omalizumab, an anti-immunoglobulin E antibody: State of the art. Drug Des Devel Ther. 2014;8:197-207.
2. Incorvaia C, Mauro M, Riario-Sforza GG, Frati F, Tarantini F, Caserini M. Current and future applications of the anti-IgE antibody omalizumab. Biologics. 2008;2:67-73.
3. Kupczyk M, Kuna P. Omalizumab in an allergology clinic: Real life experience and future developments. Postepy Dermatol Alergol. 2014;31:32-5.
4. McCormack PL. Omalizumab: A review of its use in patients with chronic spontaneous urticaria. Drugs. 2014;74:1693-9.
5. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164:S6-11.
6. Frances L, Leiva-Salinas M, Silvestre JF. Omalizumab en el tratamiento de urticaria crónica. Actas Dermosifiliogr. 2014;105:45-52.
7. Iemoli E, Piconi S, Fusi A, Borgonovo L, Borelli M, Trabattoni D. Immunological effects of omalizumab in chronic urticaria: A case report. J Investig Allergol Clin Immunol. 2010;20:252-4.
8. Babu KS, Polosa R, Morjaria JB. Anti-IgE--emerging opportunities for omalizumab. Expert Opin Biol Ther. 2013;13:765-77.
9. Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12:406-11.
10. Sockolov ME, Alikhan A, Zargari O. Non-psoriatic dermatologic uses of monoclonal antibody therapy. J Dermatolog Treat. 2009;20:319-27.
11. Viegas LP, Ferreira MB, Kaplan AP. The maddening itch: An approach to chronic urticaria. J Investig Allergol Clin Immunol. 2014;24:1-5.
12. Greaves MW. Pathology and classification of urticaria. Immunol Allergy Clin North Am. 2014;34:1-9.
13. Wedi B, Wieczorek D, Raap U, Kapp A. Urticaria. J Dtsch Dermatol Ges. 2014;12:997-1007.
14. Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: Pathophysiological and clinical implications. Intern Emerg Med. 2010;5:97-101.
15. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012;4:326-31.
16. Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337-342.
17. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011 Jul;128(1):202-209.
18. Saini SS. Chronic spontaneous urticaria: Etiology and pathogenesis. Immunol Allergy Clin North Am. 2014;34:33-52.
19. Browm MA, Hatfield JK. Mast cells are important modifiers of autoinmmune diseases: With so much evidence, why there still controversy? Front Immunol. 2012;3:147.
20. Jáuregui I, Ortiz FJ, Ferrer M, Giménez-Arnau A, Sastre J, BartraJ, et al. Assessment of severity and quality of life in chronic urticaria. J Investig Allergol Clin Immunol. 2014;24:80-6.
21. Yun J, Katelaris CH, Weerasinghe A, Adikari DB, Ratnayake C. Impact of chronic urticaria on the quality of life in Australian and Sri Lankan populations. Asia Pac Allergy. 2011;1:25-9.
22. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: The 2013 revision and update. Allergy. 2014;69:868-87.
23. Kaplan AP. Therapy of chronic urticaria: A simple, modern approach. Ann Allergy Asthma Immunol. 2014;112:419-25.
24. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122:569-73.
25. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-35.
26. Kaplan A, Ledfort D, Ashby M, Canvin J, Zazzali JN, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticarial despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101-9.
27. Ferrer M, Gamboa P, Sanz ML, Goikoetxea MJ, Cabrera-Freitag P, Javaloyes G, et al. Omalizumab is effective in non autoimmune urticaria. J Allergy Clin Immunol. 2011;127:1300-2.
28. Labrador-Horrillo M, Valero A, Velasco M, Jáuregui I, Sastre J, Bartra J, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: Analysis of 110 patients in real-life practice. Expert Opin Biol Ther. 2013;13:1225-8.
29. Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria. Allergy Asthma Proc. 2013;34:446-52.
30. Vieira Dos Santos R, Locks Bidese B, Rabello de Souza J, Maurer M. Effects of omalizumab in a patient with three types of chronic urticaria. Br J Dermatol. 2014;170:469-71.
31. Díez LS, Tamayo LM, Cardona R. Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases. Biomédica. 2013;33:503-12.
32. Thaiwat S. Sangasapaviliya A. Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J Allergy Immunol. 2011;29:357-60.
33. Fernández-AntónMartínez MC, Leis-Dosil V, Alfageme-Roldán F, Paravisini A, Sánchez-Ramón S, Suárez Fernández R. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr. 2012;103:624-8.
34. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: A randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162:89-93.
35. Quist SR, Ambach A, Göppner D, Quist J, Franke I, Bonnekoh B, et al. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E. Acta Derm Venereol. 2013;27;93:206-8.
36. Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38:496-500.
37. Lacombe J, Bégin P, Paradis L, Hatami A, Paradis J, Des Roches A. Anti-IgE therapy and severe atopic dermatitis: A pediatric perspective. J Am Acad Dermatol. 2013;69:832-4.
38. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005;53:338-40.
39. Lo Schiavo A, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: Etiology, pathogenesis, and inducing factors: Facts and controversies. Clin Dermatol. 2013;31:391-9.
40. Messingham KN, Pietras TA, Fairley JA. Role of IgE in bullous pemphigoid: A review and rationale for IgE directed therapies. Giornale Italiano di Dermatologia e Venereologia. 2012;147:251-7.
41. Messingham KA, Holahan HM, Fairley JA. Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: Lessons learned from bullous pemphigoid. Immunol Res. 2014;59:273-8.
42. Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468-74.
43. Yalcin AD, Genc GE, Celik B, Gumuslu S. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200. Clin Lab. 2014;60:523-4.
44. London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148:1241-3.
45. Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123:704-5.
46. Dufour C, Souillet AL, Chaneliere C, Jouen F, Bodemer C, Jullien D, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012;166:1140-2.
47. Ishida M, Iwai M, Kagotani A, Iwamoto N, Okabe H. Cutaneous mastocytosis with abundant eosinophilic infiltration: A case report with review of the literature. Int J Clin Exp Pathol. 2014;7:2695-7.
48. Rueda ML, Yarza ML, Colina V, Gallego S, Pereira S, Navacchia D, et al. Cutaneous mastocytosis: 10-years experience review at the Dermatology Department, Hospital General de Niños Pedro de Elizalde. Dermatol Argent. 2011;17:32-39.
49. Yalcin AD. An overview of the effects of anti-IgE therapies. Med Sci Monit. 2014;20:1691-9.
50. Beck LA, Marcotte GV, MacGlashan D Jr, Togias A, Saini S. Omalizumab-induced reductions in mast cell FceRI expression and function. J Allergy Clin Immun 2004;114:527-30.
51. Matito A, Blázquez-Goñi C, Morgado JM, Álvarez-Twose I, Mollejo M, Sánchez-Muñoz L, et al. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol. 2013;111:425-6.
52. Siebenhaar F, Kühn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocystosis and Ménière disease with anti-IgE therapy. J Allergy Clin Immunol. 2007;120:213-5.
53. Sussman G, Hébert J, Barron C, Bian J, Caron-Guay RM, Laflamme S, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol. 2014;112:170-4.
54. Song CH, Stern S, Giruparajah M, Berlin N, Sussman GL. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2013;110:113-7.
55. Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150:288-90.
56. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567-73.
57. Romano C, Sellitto A, De Fanis U, Esposito G, Arbo P, Giunta R, et al. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol. 2010;104:95-7.
58. Lefévre AC, Deleuran M, Vestergaard C. A long term case series study of the effect of omalizumab on chronic spontaneous urticaria. Ann Dermatol. 2013;25:242-5.
Cómo citar
1.
Dávila VL, Velásquez MM. Omalizumab en dermatología. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 9 de agosto de 2019 [citado 16 de agosto de 2022];23(1):39-8. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1065

Descargas

La descarga de datos todavía no está disponible.
Publicado
2019-08-09
Sección
Artículo de revisión

Artículos más leídos del mismo autor/a

<< < 1 2 3